Clinical Translation & Evidence Strategy

Emerging healthcare technologies require a structured pathway between scientific innovation and clinical application.

 

Opublu supports translational development by helping connect scientific concepts with
appropriate evidence-generation strategies.

From Scientific Innovation to Clinically Meaningful Evidence

Areas of support may include:

Translational Development Planning

Evidence-Generation Strategy

Preclinical Development Planning

Clinical-Development Strategy

Clinical-Trial Coordination

Investigator & Institutional Collaboration

Clinical Supply Coordination

Biomarker & Outcome Strategy

Evidence Documentation

Translation Toward Commercial Development

Our role is to help connect scientific and technical development with sustainable commercial opportunity.

Ocular Surface & Eyelid Observation

An exploratory case documenting visible ocular and periocular changes during a defined observation period following LagoMed Oculogics™ use.

Long-Term Contact Lens Wear & Severe Dry-Eye Symptoms

An observational case examining ocular-surface changes in an individual with a long history of contact-lens wear and significant dry-eye symptoms.

The observation contributes to the development of future research questions concerning ocular-surface recovery and contact-lens tolerance.

Periocular Redness, Ocular Sensitivity & Digital Screen Exposure

A short observational case documenting changes following seven days of LagoMed Oculogics™ use in an individual reporting ocular sensitivity, dryness and visible periocular redness associated with prolonged digital-device exposure.

Clinical Observations

Exploring Real-World Ocular Surface Responses

Observational evidence can identify clinically relevant questions that subsequently require investigation through controlled studies.

Our Evidence Development Pathway

Our Evidence Development Pathway

1. Scientific Rationale

Evaluation of published evidence surrounding MSC-derived extracellular vesicles, ocular
inflammation, immunomodulation and tissue-repair mechanisms.

2. Preclinical Evidence

Exploratory biological and ocular-surface observations supporting the development of
clinically testable hypotheses.

3. Observational Evidence

Systematic documentation of real-world observations, tolerability and clinical signals.

4. Clinical Investigation

Translation of hypotheses into structured clinical protocols with defined eligibility criteria, dosing, safety monitoring and clinical endpoints.

5. Regulatory Translation

Development of the scientific, quality, safety and clinical evidence required to support appropriate regulatory evaluation.

6. Future Clinical Development

Expansion into additional ophthalmic indications only where supported by sufficient scientific, preclinical and clinical evidence.

Scroll to Top